

The main DisMod II article describing background and methods

Barendregt JJ, Oortmarssen GJ, van, Vos T, Murray CJL. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. *Population Health Metrics*. 2003;1(1):4.

Some articles that are applications of DisMod II, most recent first

1. Yang L-P, Liang S-Y, Wang X-J, Li X-J, Wu Y-L, Ma W. Burden of Disease Measured by Disability-Adjusted Life Years and a Disease Forecasting Time Series Model of Scrub Typhus in Laiwu, China. *PLoS neglected tropical diseases*. 2015;9(1):e3420.
2. Wang C, Cui Y, Li Y, Liu X, Han J. A systematic review of hereditary spherocytosis reported in Chinese biomedical journals from 1978 to 2013 and estimation of the prevalence of the disease using a disease model. *Intractable & rare diseases research*. 2015;4(2):76.
3. Sözmen K, Unal B, Capewell S, Critchley J, O'Flaherty M. Estimating diabetes prevalence in Turkey in 2025 with and without possible interventions to reduce obesity and smoking prevalence, using a modelling approach. *International journal of public health*. 2015;60(1):13-21.
4. McLean S, Barbour V, Wild S, Simpson C, Sheikh A. Models for estimating projections for disease prevalence and burden: a systematic review focusing on chronic obstructive pulmonary disease. *Journal of health services research & policy*. 2015:1355819615579232.
5. Maredza M, Bertram MY, Tollman SM. Disease burden of stroke in rural South Africa: an estimate of incidence, mortality and disability adjusted life years. *BMC neurology*. 2015;15(1):54.
6. Yoon S-J, Oh I-H, Seo H-Y, Kim E-J. Measuring the burden of disease due to climate change and developing a forecast model in South Korea. *Public health*. 2014;128(8):725-33.
7. Steckling N, Bose-O'Reilly S, Pinheiro P, Plass D, Shoko D, Drasch G, et al. The burden of chronic mercury intoxication in artisanal small-scale gold mining in Zimbabwe: data availability and preliminary estimates. *Environmental Health*. 2014;13(1):111.
8. Patten SB. The Global Burden of Disease 2010 update: keeping mental health in the spotlight. *Epidemiology and psychiatric sciences*. 2014;23(03):255-7.
9. Ibinda F, Wagner RG, Bertram MY, Ngugi AK, Bauni E, Vos T, et al. Burden of epilepsy in rural Kenya measured in disability-adjusted life years. *Epilepsia*. 2014;55(10):1626-33.
10. Borja MP, Cruz EL, Tan AG, Mortera LL, Reganit PFM. Smoking-attributable burden of lung cancer in the Philippines. *Tobacco control*. 2014:tobaccocontrol-2013-051082.
11. Baxter A, Ferrari A, Erskine H, Charlson F, Degenhardt L, Whiteford H. The global burden of mental and substance use disorders: changes in estimating burden between GBD1990 and GBD2010. *Epidemiology and psychiatric sciences*. 2014;23(03):239-49.
12. Ver Luanni FB, Borja MP, Cruz EL, Tan AG, Mortera LL, Reganit PFM. Smoking-attributable burden of lung cancer in the Philippines: a comparative risk assessment. *The Lancet*. 2013;381:S15.
13. Park J-H, Eum J-H, Bold B, Cheong H-K. Burden of disease due to dementia in the elderly

- population of Korea: present and future. *BMC public health*. 2013;13(1):293.
14. Lhachimi S, Nusselder W, Lobstein T, Smit H, Baili P, Bennett K, et al. Modelling obesity outcomes: reducing obesity risk in adulthood may have greater impact than reducing obesity prevalence in childhood. *obesity reviews*. 2013;14(7):523-31.
 15. Chen C-Y, Huang Y-B, Tzu-Chi Lee C. Epidemiology and disease burden of ischemic stroke in Taiwan. *International Journal of Neuroscience*. 2013;123(10):724-31.
 16. Bertram MY, Jaswal AV, Van Wyk VP, Levitt NS, Hofman KJ. The non-fatal disease burden caused by type 2 diabetes in South Africa, 2009. *Global health action*. 2013;6.
 17. Al Ali R, Mzayek F, Rastam S, Fouad FM, O'Flaherty M, Capewell S, et al. Forecasting future prevalence of type 2 diabetes mellitus in Syria. *BMC public health*. 2013;13(1):507.
 18. Gouda H, Powles J, Barendregt JJ, Emerson P, Ngondi J. The burden of trachoma in South Sudan: assessing the health losses from a condition of graded severity. *PLoS Neglected Tropical Diseases*. 2012;6(3):e1538.
 19. Chimura H, Hirao T, Seki E, Araki K, Satoh T. Disease burden estimates for lung cancer in Japan. *Kitsasto Med J* 2012; 42: 76. 2012;82.
 20. Abu-Rmeileh NM, Husseini A, O'Flaherty M, Shoaibi A, Capewell S. Forecasting prevalence of type 2 diabetes mellitus in Palestinians to 2030: validation of a predictive model. *The Lancet*. 2012;380:S21.
 21. Katzenellenbogen JM, Vos T, Somerford P, Begg S, Semmens JB, Codde JP. Burden of stroke in indigenous Western Australians a study using data linkage. *Stroke*. 2011;42(6):1515-21.
 22. Agardh EE, Sidorchuk A, Hallqvist J, Ljung R, Peterson S, Moradi T, et al. Burden of type 2 diabetes attributed to lower educational levels in Sweden. *Popul Health Metr*. 2011;9:60.
 23. Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. *Popul Health Metr*. 2010;8:24.
 24. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. *The Lancet Neurology*. 2009;8(4):345-54.
 25. Fernandez de Larrea-Baz N, Alvarez-Martin E, Morant-Ginestar C, Genova-Maleras R, Gil A, Perez-Gomez B, et al. Burden of disease due to cancer in Spain. *BMC public health*. 2009;9:42.
 26. Cobiac L, Vos T, Barendregt JJ. Cost-Effectiveness of Interventions to Promote Physical Activity: A Modelling Study. *PLoS Med*. 2009;6(7):e1000110.
 27. Villaverde-Hueso A, de la Paz MP, Martin-Arribas MC, Sanchez-Valle E, Ramirez-Gonzalez A, Baiardi P. Prevalence of scleroderma in Spain: an approach for estimating rare disease prevalence using a disease model. *Pharmacoepidemiology and drug safety*. 2008;17(11):1100-7.
 28. Saha S, Barendregt JJ, Vos T, Whiteford H, McGrath J. Modelling disease frequency measures in schizophrenia epidemiology. *Schizophr Res*. 2008;104(1-3):246-54.

29. Lapostolle A, Lefranc A, Gremy I, Spira A. Sensitivity analysis in summary measure of population health in France. *Eur J Public Health*. 2008;18(2):195-200.
30. Chisholm D, Gureje O, Saldivia S, Villalon Calderon M, Wickremasinghe R, Mendis N, et al. Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. *Bulletin of the World Health Organization*. 2008;86(7):542-51.
31. Basiri A, Mousavi SM, Naghavi M, Araghi IA, Namini SA. Urologic diseases in the Islamic Republic of Iran: what are the public health priorities? *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*. 2008;14(6):1338-48.
32. Manuel DG, Lim JJ, Tanuseputro P, Stukel TA. How many people have had a myocardial infarction? Prevalence estimated using historical hospital data. *BMC public health*. 2007;7:174.
33. Heidrich J, Wellmann J, Heuschmann PU, Kraywinkel K, Keil U. Mortality and morbidity from coronary heart disease attributable to passive smoking. *European heart journal*. 2007;28(20):2498-502.
34. Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and disability--adjusted life--years. *Malaria journal*. 2007;6:97.
35. Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z. Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. *Asian Pacific journal of cancer prevention : APJCP*. 2006;7(4):571-4.
36. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. *The Lancet*. 2006;366(9503):2112-7.
37. Ayuso-Mateos J, Gutierrez-Recacha P, Haro J, Chisholm D. Estimating the prevalence of schizophrenia in Spain using a disease model. *Schizophrenia research*. 2006;86(1):194-201.
38. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The Burden of Mortality Attributable to Diabetes Realistic estimates for the year 2000. *Diabetes care*. 2005;28(9):2130-5.
39. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet*. 2005;366(9503):2112-7.
40. Barendregt JJ, Ott A. Consistency of epidemiologic estimates. *European Journal of Epidemiology*. 2005;20(10):827-32.
41. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. *Diabetes care*. 2004;27(5):1047-53.
42. Kruijshaar ME, Barendregt JJ, the European Disability Weights Group. The breast cancer related burden of morbidity and mortality in six European countries: The European Disability Weights projects. *Eur J Public Health*. 2004;14(2):141-6.
43. Kruijshaar ME, Barendregt JJ, Hoeymans N. The use of models in the estimation of disease epidemiology. *Bull WHO*. 2002;80(8):622-8.